

16 June 2014

The Company Announcements Platform
ASX Limited
By E-lodgement

Virax New Managing Director to Present at International Life Sciences Showcase

16 June 2014: 2014, Melbourne, Australia: The new managing director of Virax Holdings Limited (ASX:VHL) will outline the company's technology and investment opportunity to the international life sciences community at an important biotechnology conference in the US later this week.

Dr Rob Crombie, whose appointment is effective today, is a key presenter at the Australian Life Sciences Showcase being staged in San Francisco on 20 June.

The event brings together US venture capitalists, fund managers, angel investors and investment bankers, providing opportunities for financing and collaboration with Australian biotechnology companies.

Dr Crombie commented: "I look forward to outlining the company and its highly promising oncology technologies to the US investment community."

"Virax has an outstanding technical portfolio which has been substantially strengthened by the recent acquisition of US specialty oncology company Pathway Oncology."

"The company is at a critical stage of development, with multiple programs across various cancer indications. Virax is committed to progressing these programs through clinical trials at the earliest opportunity. Engaging with the US investment community and potential collaboration partners is critical to this process."

Virax chairman Dr Wayne Millen said Dr Crombie's appointment was key to the company's clinical and commercial agenda.

He commented: "Virax is extremely fortunate to attract a managing director of this calibre – not only does Dr Crombie have significant commercial experience, he also has an exemplary scientific background in cancer research."

"Our company is on the cusp of some extremely promising clinical and commercial opportunities. Dr Crombie is the right person to aggressively drive our programs forward and create shareholder value."

Dr Crombie brings high quality Australian and global life science commercial experience to the company, including senior management roles at Arana Therapeutics and EvoGenix Ltd.

He was instrumental in driving Arana from start-up phase through an IPO and toward a \$318 million cash sale within five years.

Ends.

For further information contact:

Mr. Rudi Michelson

Monsoon Communications

Ph: +61 (0) 3 9620 3333

Dr. Rob Crombie

Managing Director

Ph: +61 (0) 439 361 331

About Virax

Virax is a biopharmaceutical company currently engaged in the discovery and development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer. In addition, the company has granted a licence to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products. These are: TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to oropharyngeal(head and neck) cancer, and TG4010 – a treatment for non-small cell lung cancer (NSCLC). The board is actively seeking to expand its asset base with complementary technologies and products to maximise shareholder value.